Teva Pharma Industries Ltd ADR

Yahoo Finance • 11 days ago

Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer

Company Logo The polymyositis market is witnessing notable growth driven by the increasing prevalence of this autoimmune disease, particularly among older adults. Polymyositis leads to muscle inflammation and weakness, highlighting the ur... Full story

Yahoo Finance • 12 days ago

TrumpRx set to expand into generic medicines with Mark Cuban

Heather Diehl/Getty Images News * Mark Cuban, the billionaire co-founder of the Cost Plus Drugs online pharmacy, is expected to join President Trump Monday afternoon as part of an announcement that the TrumpRx website will now carry gen... Full story

Yahoo Finance • 12 days ago

Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution

TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to Investment Grade BBB-, w... Full story

Yahoo Finance • 14 days ago

Teva Pharmaceutical (TEVA) Reports Q1 Beat, Plans Amylyx Deal

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best Middle East and Africa stocks to buy according to hedge funds. On April 29, Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported its Q1 FY2026 earnings, where it... Full story

Yahoo Finance • 15 days ago

Glenview adds Humana, exits Expedia, reduces Teva among Q1 trades

[Teva logo on its USA headquarters building in Parsippany, NJ, USA.] JHVEPhoto Glenview Capital Management added Humana (HUM [https://seekingalpha.com/symbol/HUM]), Cisco (CSCO [https://seekingalpha.com/symbol/CSCO]), Baker Hughes (BKR [h... Full story

Yahoo Finance • 16 days ago

Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More.

Key Points Teva is pivoting from generic-drug maker to major pharmaceutical company. Even after more than doubling in price over the past year, shares have more room to run, thanks to the company's robust pipeline. Further modest gains ma... Full story

Yahoo Finance • 23 days ago

Alvotech Q1 Earnings Call Highlights

Alvotech logo Key Points FDA inspection at Alvotech’s Reykjavik facility is underway and Biologics License Application resubmissions for multiple biosimilars are in the final stage, with the company planning resubmissions in Q2 and targe... Full story

Yahoo Finance • 26 days ago

How The Investment Story For Teva Pharmaceutical Industries (TEVA) Is Shifting With New Analyst Focus

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Teva Pharmaceutical Industries has seen its fair value estimate move to US$40.09 from US$38.18,... Full story

Yahoo Finance • 27 days ago

Is Deckers Outdoor Corporation (DECK) A Good Stock To Buy Now?

Is DECK a good stock to buy? We came across a bullish thesis on Deckers Outdoor Corporation on The Wealth Dynasty Report’s Substack. In this article, we will summarize the bulls’ thesis on DECK. Deckers Outdoor Corporation's share was trad... Full story

Yahoo Finance • 27 days ago

Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy Now?

Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries... Full story

Yahoo Finance • 28 days ago

Teva (TEVA) Enters a New $700 Million Acquisition Deal

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like.Teva (TEVA) Enters a New $700 Million Acquisition Deal On April 29, 2026, Teva Pharmaceutical Industries Limited (N... Full story

Yahoo Finance • 28 days ago

Teva Pharmaceutical Industries Q1 Earnings Call Highlights

Teva Pharmaceutical Industries logo Key Points Teva reported Q1 revenue of $4.0 billion (‑1% y/y) with adjusted EBITDA up 2% to $1.1 billion and non‑GAAP EPS of $0.53, while its innovative portfolio grew 41% led by Austedo ($578M, +41%),... Full story

Yahoo Finance • 30 days ago

Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?

Key Points Blackstone committed $400 million to fund development of Teva's promising autoimmune disease drug duvakitug. This deal reflects a bet on Teva's future. Others are also recognizing Teva's turnaround story.10 stocks we like bette... Full story

Yahoo Finance • last month

Teva Pharmaceutical (TEVA): David Einhorn Likes This Pharma Stock

We just covered 15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026 and Teva Pharmaceutical Industries Limited (NYSE:TEVA) ranks 2nd on this list. Institutional sentiment towards Teva Pharmaceutical Industries Lim... Full story

Yahoo Finance • last month

Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - Kaken Pharma, Novartis, Glenmark Pharma, Sun Pharma, Teva Pharmaceutical, Bayer, and Galderma

Company Logo The global dermatomycoses market is poised for significant growth, fueled by rising superficial fungal infections, increased hygiene awareness, and a growing immunocompromised population. These fungal infections are primarily... Full story

Yahoo Finance • last month

H.C. Wainwright Initiates Coverage of Evotec (EVO) with a Buy Rating

Evotec SE (NASDAQ:EVO) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 14, 2026, H.C. Wainwright assumed coverage of Evotec SE (NASDAQ:EVO) with a Buy rating and a $7 price target, citing the company’s shift from a... Full story

Yahoo Finance • last month

Teva Pharmaceutical Industries Limited (TEVA): David Einhorn Trims Holding

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is featured on the David Einhorn Stock Portfolio: Top 10 Stock Picks. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has featured in the 13F portfolio of Greenlight Capital since the... Full story

Yahoo Finance • last month

3 Catalysts That Could Send Teva Stock to $40 and Beyond

Key Points FDA approval of long-acting schizophrenia drug olanzapine could be Teva's biggest near-term catalyst. Teva's specialty drugs continue to gain momentum. The drugmaker should also experience a biosimilar boom over the next couple... Full story

Yahoo Finance • last month

Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

ALTERITY THERAPEUTICS LIMITED MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease... Full story

Yahoo Finance • last month

Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground™ Schizophrenia Community is a centralized destination that delivers peer-driven insights, tools an... Full story